GGrantIndex
Sort

130,381 grants matching hiv

HIV Infection In Vivo And In Vitro

$1,273,878
Richard A Koup · National Institute Of Allergy And Infectious Diseases · ZIA · FY2012 · AI

HIV/SIV Replication In Vivo

$1,273,878
Richard A Koup · National Institute Of Allergy And Infectious Diseases · ZIA · FY2013 · AI

HIV Infection In Vivo And In Vitro

$1,273,878
Richard A Koup · National Institute Of Allergy And Infectious Diseases · ZIA · FY2011 · AI

HIV Sexual Risk-Reduction for African-American Couples

$1,273,780
Emory University · U10 · FY2003 · MH

INTERNATIONAL TRAINING GRANT IN EPIDEMIOLOGY RELATED TO

$1,273,691
University Of California Los Angeles · D43 · FY2002 · TW

HIV Testing and Treatment to Prevent Onward HIV Transmission among High-risk MSM

$1,273,480
Ann C Duerr · Fred Hutchinson Cancer Research Center · R01 · FY2014 · DA

Harnessing B cells for TB vaccine development to improve therapy of TB and TB-HIV coinfection

$1,273,323
Martin Alfons Gengenbacher · Hackensack University Medical Center · R01 · FY2024 · AI

AIDS INTERNATIONAL TRAINING AND RESEARCH PROGRAM

$1,273,246
University Of Washington · D43 · FY2002 · TW

Administrative Core

$1,273,196
David Mitchell Smith · University Of California, San Diego · P30 · FY2022 · AI

Drive to Zero: Developing a digital cohort to understand the drivers of non-sustained viral suppression in the Deep South

$1,273,106
Aadia Rana · University Of Alabama At Birmingham · UG3 · FY2023 · AI

New York University HIV/AIDS Clinical Trial Unit

$1,273,058
Judith Ann Aberg · New York University School Of Medicine · U01 · FY2007 · AI

Development of Ultra Long-Acting Oral HIV Therapies

$1,272,821
Andrew Martin Bellinger · Lyndra Therapeutics, Inc. · R01 · FY2020 · AI

Development of Ultra Long-Acting Oral HIV Therapies

$1,272,821
Stephen Zale · Lyndra Therapeutics, Inc. · R01 · FY2021 · AI

Noncoding RNAs in gamma-Herpesvirus Biology and AIDS Malignancies

$1,272,666
Rolf F Renne · University Of Florida · P01 · FY2019 · CA

Crosstalk Among Oral & Gastrointestinal Soluble Innate Factors, HIV, & Microbes

$1,272,576
Daniel Malamud · New York University · U19 · FY2011 · DE

India International Center for Excellence in Research

$1,272,313
Thomas Nutman · National Institute Of Allergy And Infectious Diseases · ZIA · FY2017 · AI

Project 1: Development of Nucleoside-Modified mRNAs Encoding Sequential HIV-1 Envelopes for Initiation of V3-glycan Neutralizing Antibody Lineages

$1,272,291
Barton F Haynes · Duke University · U19 · FY2018 · AI

Expertise in Using Bitter Taste Receptor Blockers to Improve the Palatability of Pediatric Medicines: Blocker Discovery

$1,272,115
Peter Silvera · Advanced Bioscience Laboratories, Inc. · N01 · FY2025 · AI

PS12-1201 COMPREHENSIVE HIV PREVENTION PROJECT FOR HEALTH DEPTS

$1,272,065
Jennifer Brown · Utah State Department Of Health · U62 · FY2012 · PS

Vectored HIV Immunotherapy via in vivo B cell editing

$1,272,001
David T Curiel · Washington University · R01 · FY2025 · AI

Biology of T Cell Depletion

$1,271,859
Crystal Mackall · Division Of Basic Sciences - Nci · ZIA · FY2010 · CA

HPV &CERVIX NEOPLASIA IN A LARGE, LONG TERM HIV+ COHORT

$1,271,722
Yeshiva University · R01 · FY2003 · CA

Research Resource for Human Organs and Tissues

$1,271,624
Gene C Kopen · National Disease Research Interchange · U42 · FY2017 · OD

IMPLEMENTING NEW DIRECTIONS IN HIV PREVENTION IN SAN FRANCISCO: A COMPREHENSIVE C

$1,271,584
Tracey Packer · Public Health Foundation Enterprises · U65 · FY2011 · PS

LEVERAGEING MMC FOR HIV PREVENTION IN KWAZULU-NATAL

$1,271,431
Malebo Maponyane · Catholic Medical Mission Board, Inc. · U2G · FY2012 · GH